Ketoconazole
Nizoral
Also known as: Sporanox
CYP3A4 inhibitor + QTc prolongation.
Severity
Moderate caution
Mechanism
CYP3A4 metabolism overlap
Protocol Status
Pre-arrival washout (under your prescribing physician)
Restart Delay
Physician discretion
What "Moderate caution" Means
Use with caution. Often requires a brief hold, dose reduction, or enhanced monitoring rather than full discontinuation.
Clinical Action
Discontinue minimum 7 days before treatment.
Where the Washout Happens
Pre-arrival washout (under your prescribing physician)
Discontinuation is completed before arrival, under the patient's own prescribing physician, with the medication-specific washout interval observed before the flood dose.
Pre-Treatment Washout Window
Hold on dosing day; physician-directed timing.
Post-Treatment Restart
Restart at physician discretion once acute window closes.
The Pharmacology
CYP3A4 is the second major hepatic clearance pathway. Strong CYP3A4 inhibitors (some antifungals, macrolides, and protease inhibitors) extend the elimination of ibogaine and several co-medications, while strong inducers can cause sub-therapeutic exposure. Either direction destabilises a treatment that depends on tightly controlled plasma kinetics.
Same Mechanism
Same Severity Tier
QT-interval prolongation
Zofran
QT-interval prolongation
Zithromax, Z-Pack
Cardiac conduction (bradycardia / AV node)
Lopressor, Toprol
Cardiac conduction (bradycardia / AV node)
Tenormin
Cardiac conduction (bradycardia / AV node)
Inderal
Cardiac conduction (bradycardia / AV node)
Coreg
Common Questions
Moderate caution. CYP3A4 inhibitor + QTc prolongation. Discontinue minimum 7 days before treatment.
Pre-arrival washout (under your prescribing physician). Discontinuation is completed before arrival, under the patient's own prescribing physician, with the medication-specific washout interval observed before the flood dose. Hold on dosing day; physician-directed timing.
CYP3A4 metabolism overlap. CYP3A4 is the second major hepatic clearance pathway. Strong CYP3A4 inhibitors (some antifungals, macrolides, and protease inhibitors) extend the elimination of ibogaine and several co-medications, while strong inducers can cause sub-therapeutic exposure. Either direction destabilises a treatment that depends on tightly controlled plasma kinetics.
In many cases yes. Our medical team works with your prescribing physician to taper or substitute medications safely before treatment. The right substitution depends on the underlying condition you are treating with Itraconazole — contact us for an individual review.
Checking more than one medication? Use the interactive Drug Interaction Checker to screen your full medication list at once.
Browse all 103 medications in the A–Z directory.